Entropy Neurodynamics Advances Psilocin Platform With BED Trial Progress and New Patent

The latest announcement is out from Tryptamine Therapeutics ( (AU:ENP) ).

Entropy Neurodynamics reported strong clinical and operational progress in the March 2026 quarter, highlighted by early data from its world-first Phase 2 trial of TRP-8803 in Binge Eating Disorder. The first patient treated showed clinically meaningful improvements across binge eating severity, mood, body image, sleep and overall wellbeing, while all patients dosed so far have exhibited controlled, reproducible psychedelic responses that support the platform’s precision-controlled IV approach.

The company also completed enrolment of the first six-patient cohort in the TRP-8803 BED trial, with dosing on schedule and full cohort results expected after dosing concludes this quarter. Broader program validation came from peer-reviewed Phase 2a data on oral psilocybin candidate TRP-8802, which showed about an 80% reduction in binge episodes and sustained psychological and metabolic benefits, bolstering the case for TRP-8803 as a scalable next-generation therapy.

Intellectual property was strengthened by the grant of an Australian patent protecting the precision-controlled, two-phase IV dosing method that underpins TRP-8803 until 2042, enhancing the company’s competitive moat and supporting potential expansion into multiple neuropsychiatric indications. With $9.1 million in available funding at quarter end, Entropy says it is positioned to continue disciplined clinical execution, progress into the second cohort of the BED study, and initiate additional clinical trials in the near term.

More about Tryptamine Therapeutics

Entropy Neurodynamics Limited is a clinical-stage biotechnology company focused on developing psychedelic-assisted therapies for neuropsychiatric disorders. Its lead assets, TRP-8803, an intravenously infused psilocin formulation, and TRP-8802, an oral psilocybin product, target conditions such as Binge Eating Disorder using precision-controlled dosing and supportive psychotherapy.

Average Trading Volume: 2,257,144

Technical Sentiment Signal: Strong Sell

Current Market Cap: A$53.85M

Learn more about ENP stock on TipRanks’ Stock Analysis page.